SESophiko Erbel-Khurtsidze

Sophiko Erbel-Khurtsidze

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sophiko Erbel-Khurtsidze has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Artur Lichtenberg

    Klinik für Herzchirurgie, Universitätsklinikum Düsseldorf, Heinrich-Heine-Universität, Düsseldorf, Deutschland

    1 shared publication
  • Artur Lichtenberg

    Department of Cardiac Surgery and Research Group for Experimental Surgery, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Hospital, Düsseldorf, Germany

    1 shared publication
  • Detlef Moka

    Zentrum für Nuklearmedizin, Essen, Deutschland

    1 shared publication
  • Hug Aubin

    Department of Cardiac Surgery, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, 40225 Düsseldorf, Germany

    1 shared publication
  • Igor Tudorache

    Department of Cardiac Surgery, Medical Faculty, Heinrich-Heine University, 40225 Düsseldorf, Germany

    1 shared publication
  • Katja Brandt-mAinz

    Zentrum für Nuklearmedizin, Essen, Deutschland

    1 shared publication

Latest Publications

  • Open Access

    Heart Transplantation of the Elderly—Old Donors for Old Recipients: Can We Still Achieve Acceptable Results?

    by Moritz Benjamin Immohr, Hug Aubin, Ralf Westenfeld, Sophiko Erbel-Khurtsidze, Igor Tudorache, Payam Akhyari, Artur Lichtenberg, Udo Boeken

    As society is ageing, an increasing prevalence of elderly heart failure patients will be expected. In order to increase the donor pool, acceptance of older donors might be a reasonable choice. All patients undergoing heart transplantation between 2010 and 2021 at a single department were retrospectively reviewed and divided into different study groups with regard to recipient (≤60 years (RY) or >60 years (RO)) and donor age (≤50 years (DY) or >50 years (DO). A total of n = 201 patients were included (DY/RY, n = 91; DO/RY, n = 38; DY/RO, n = 41; DO/RO, n = 31). Neither incidence of severe primary graft dysfunction (p = 0.64) nor adverse events, such as kidney failure (p = 0.27), neurological complications (p = 0.63), infections (p = 0.21) or acute graft rejection (p = 1.00), differed between the groups. However, one-year survival was impaired in the DO/RO group (56.0%) compared to the other groups (DY/RY: 86.1%, DY/RO: 78.8%, DO/RY: 74.2%, p = 0.02). Given the impaired one-year survival, acceptance of grafts from old donors for old recipients should be performed with caution and by experienced centres only. Nevertheless, because of the otherwise dismal prognosis of elderly heart failure patients, transplantation of patients may still improve the therapy outcome.


  • Kardiale Amyloidose und Aortenklappenstenose

    by Sophiko Erbel-Khurtsidze, Rainer Seibel, Detlef Moka, Katja Brandt-mAinz, Raimund Erbel, Artur Lichtenberg

    Zusammenfassung Die Aortenklappenstenose im höheren Alter ist in den Blickpunkt der Kardiologie und Herzchirurgie gerückt, nachdem transvaskuläre und transluminale minimal-invasive Verfahren zur Klappenimplantation entwickelt worden waren. Die Beobachtung von Amyloidablagerungen in operativ entfernten Klappen führte zur Diagnostik der Amyloidose des Myokards, die bei bis zu 20 % der Patienten, die zur Klappenimplantation kommen, aufgedeckt wurde. Klinische Zeichen wie Karpaltunnelsyndrom oder Bizepssehnenruptur sind zu beachten. Eine wichtige diagnostische Rolle spielt neben EKG, Echokardiogramm und Magnetresonanztomographie die 99mTechnetium-Knochenszintigraphie. Das Zusammentreffen von Aortenklappenstenose und Amyloidose erklärt die besondere hämodynamische Situation eines niedrigen Gradienten, mit niedrigem Blutfluss bei hochgradiger Klappeneinengung. Die interventionelle oder chirurgische Klappenimplantation verbessert die Prognose dieser Patienten ähnlich wie bei reiner Aortenklappenstenose, gefolgt von einer spezifischen medikamentösen Therapie in Abhängigkeit vom Amyloidosetyp.